Imagine a world where a common, affordable antibiotic could be the key to fighting a deadly form of tuberculosis that attacks the brain. Sounds too good to be true, right? But here's where it gets exciting: researchers at the National University of Singapore (NUS Medicine) have discovered that doxycycline, a widely available and inexpensive antibiotic, could significantly improve survival rates and neurological outcomes for patients with central nervous system tuberculosis (CNS-TB). This groundbreaking finding, published in the Journal of Neuroinflammation, offers a glimmer of hope for a condition that’s often fatal and notoriously difficult to treat.
Led by Associate Professor Catherine Ong Wei Min, along with Dr. Poh Xuan Ying and Dr. Loh Fei Kean, the study delved into the prognostic factors of CNS-TB. By analyzing cerebrospinal fluid samples from 72 children with tuberculous meningitis, the team uncovered a critical insight: elevated levels of tissue-damaging proteins called matrix metalloproteinases (MMPs) and immune cell traps known as neutrophil extracellular traps (NETs) were driving the severity of the disease. And this is the part most people miss: while tuberculosis is commonly associated with the lungs, CNS-TB is a far more severe form that targets the brain and spinal cord, disproportionately affecting children and immunocompromised individuals.
To tackle this, the researchers developed a laboratory model of CNS-TB that mimicked the brain pathology and neurological symptoms seen in humans. Using advanced RNA sequencing, they analyzed gene expression changes in infected tissue samples. Here’s where doxycycline stole the show: when combined with standard TB drugs, it suppressed MMPs and NETs, reduced inflammation, preserved brain tissue, and improved vascular integrity. The result? Significantly better survival rates and outcomes in preclinical models.
But here’s the controversial part: Could a drug as simple and affordable as doxycycline really revolutionize the treatment of such a complex disease? Assoc. Prof. Ong believes so. She notes, ‘Doxycycline’s accessibility and safety profile mean it could be rapidly integrated into national TB programs, bypassing the lengthy delays of new drug development—if Phase II studies confirm our findings.’ This raises a thought-provoking question: Are we overlooking the potential of repurposing existing drugs in favor of chasing novel treatments?
Globally, TB remains a pressing health threat, with over 10.8 million active cases reported in 2023. In Singapore alone, endemic transmission persists, with approximately 1,100 new cases in 2024. CNS-TB, though rare (1-2% of global TB cases), continues to cause devastating neurological damage and high mortality rates, even with standard treatment. This study highlights the untapped potential of repurposing well-tolerated, inexpensive drugs like doxycycline to address such challenges.
The findings have already sparked a Phase II clinical trial across Singapore, Malaysia, and Indonesia, testing whether adding doxycycline to standard TB treatment can improve survival and reduce brain damage in patients. As Assoc. Prof. Ong puts it, ‘We’re aiming to create a robust clinical dataset that paves the way for more targeted and effective TB treatments, giving patients a better shot at full recovery.’
What do you think? Is repurposing existing drugs the future of tackling complex diseases like CNS-TB? Or should we focus on developing entirely new treatments? Let us know in the comments below!
For more details, check out the full study: MMPs and NETs are detrimental in CNS-tuberculosis with MMP Inhibition in CNS-tuberculosis mice improving survival.
